Technology
Dimerix unveils ‘tremendous’ top-line results for lead drug in treating rare kidney disorder – Small Caps
Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage ki…
Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads to end-stage kidney failure.
Dimerix received orphan drug designation for DMX-200 in November 2018 in both the US and Europe for the treatment of FSGS, after repurposing the drug based on preliminary non-clinical data which showed a reduction in the numbe…
-
Noosa News17 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
General13 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News22 hours agoBrisbane news live: Federal fund for council’s cyclone clean-up dries up
-
Noosa News15 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia